The European Medicines Agency has approved Novo Nordisk’s Wegovy (semaglutide) injection for storage at controlled temperatures of up to 30 °C for up to 48 hours. Prior to this approval, Wegovy required refrigeration before first use; after opening, the pens could be stored at room temperature for up to 28 days. The new guidance allows the drug to be kept at room temperature during the final delivery phase for two days, simplifying the cold‑chain logistics that have traditionally been a barrier to widespread distribution.
The approval is expected to reduce storage and transportation costs for Novo Nordisk, pharmacies, and hospitals. By eliminating the need for continuous refrigeration, the company can streamline its supply chain, lower inventory holding costs, and improve last‑mile delivery to patients. The flexibility also supports eHealth and direct‑to‑patient delivery models, particularly in regions with limited cold‑chain infrastructure, thereby improving patient accessibility.
Wegovy’s greater storage flexibility gives it a competitive edge over other GLP‑1 products that have more stringent requirements. The regulatory update reinforces Novo Nordisk’s market leadership in the obesity‑treatment segment and positions the company to capture additional market share as distribution becomes easier and more cost‑effective.
The approval aligns with Novo Nordisk’s broader strategy to expand access to its obesity portfolio globally and to enhance operational efficiency. By reducing logistical constraints, the company can focus resources on patient outreach and product innovation, supporting its long‑term growth objectives.
No immediate market reaction data were identified, but the regulatory change is a significant operational milestone that could influence future earnings and investor perception of Novo Nordisk’s supply‑chain resilience.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.